Innate Pharma to Spotlight Oncology Pipeline at H.C. Wainwright Investor Conference
I'm LongbridgeAI, I can summarize articles.Innate Pharma SA will participate in the H.C. Wainwright 28th Annual Global Investment Conference (Sept 14-16, 2026) via fireside chats and investor meetings. The company aims to highlight its oncology pipeline, including Nectin-4 ADC IPH4502 and partnered assets, to deepen financial community engagement and reinforce its position in immuno-oncology.
Innate Pharma SA ( (FR:IPH) ) just unveiled an update.
Innate Pharma SA said members of its executive team will join a fireside chat and hold one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference in New York from September 14 to 16, 2026. The company will webcast the September 14 session, offering investors remote access and a replay, underscoring its efforts to deepen engagement with the financial community while highlighting its oncology-focused antibody and ADC pipeline and key partnerships.
The planned participation at the high-profile investment event supports Innate Pharma’s visibility as a dual-listed, clinical-stage biotech pursuing first- and best-in-class cancer immunotherapies. By showcasing assets such as its lead Nectin-4 ADC, as well as partnered programs in cutaneous T-cell lymphomas and non-small cell lung cancer, the company aims to reinforce its positioning in immuno-oncology and potentially broaden interest from institutional investors and strategic partners.
More about Innate Pharma SA
Innate Pharma SA is a clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. Leveraging expertise in antibody engineering and target identification, it is building a portfolio of next-generation antibody therapeutics, notably antibody-drug conjugates. The pipeline includes its proprietary Nectin-4 ADC IPH4502 for solid tumors and preclinical ADC candidates, alongside partnered late-stage assets lacutamab with Sobi for cutaneous T-cell lymphomas and monalizumab with AstraZeneca for non-small cell lung cancer. The company collaborates with major biopharmaceutical groups such as Sobi, Sanofi and AstraZeneca, as well as leading academic institutions, and is headquartered in Marseille, France, with dual listings on Euronext Paris and Nasdaq.
Average Trading Volume: 377,739
Technical Sentiment Signal: Buy
Current Market Cap: €209.5M
See more insights into IPH stock on TipRanks’ Stock Analysis page.